Marrow damage from chemo-and radiation therapy can lead to poor CD341 cell mobilization. Such therapies have also been suggested to affect quality of CD341 cells. We tested the hypothesis that CD341 cells from low mobilizers are qualitatively inferior to CD341 cells from high mobilizers.
Evaluation of days to neutrophil engraftment among the mobilization groups did not show a statistically significant difference (p 5 0.1). However, days to platelet engraftment among the mobilization groups was statistically significantly different (p 5 0.05). This finding may not be clinically significant. In summary, the proportion of primitive CD341 cells in HPC products and days to neutrophil engraftment were not influenced by CD341 cell mobilization capacity. The quality of CD341 cells from low mobilizers was comparable to CD341 cells from high mobilizers. Prior therapies may affect the quantity but not the quality of CD341 cells.
CYCLOPHOSPHAMIDE (CY)/G-CSF CANNOT COMPLETELY OVERCOME IMID-INDUCED IMPAIRMENT OF PERIPHERAL BLOOD STEM CELL (PBSC) MOBILIZATION (MOB) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
Osman, S., Kanate, A., Bunner, P., Leadmon, S., Hart, K., Goff, L., Tse, W., Cumpston, A., Remick, S., Abraham, J., Craig, M., Hamadani, M. West Virginia University Hospitals, Morgantown, WV Novel agents are routinely used as induction therapy for MM, but there is concern about their impact on PBSC Mob. Some studies suggest that CY/G-CSF Mob may overcome suppressive effects of lenalidomide on PBSC Mob, however an optimal mobilization strategy for this population remains controversial.
We report here PBSC collection outcomes of 107 consecutive MM patients, who uniformly underwent Mob with CY (1.5mg/m 2 ) and G-CSF (10mg/kg/day). 44 patients received older induction therapies, while 63 received novel agents (including; lenalidomide-(n 5 13), bortezomib-(n 5 15) and IMiD-(n 5 49) containing regimens). Mob parameters including, peak peripheral blood (PB) CD341 count, CD341 cell yield on day1, total CD341 cell yield, and number of apheresis sessions were analyzed relative to induction regimens. Mobilization failure was defined as failure to collect $ 2 Â 10 6 cells/Kg body weight. The median patient age was 57yrs. The median number of prior therapies was one, while 29% received prior radiation. Compared to older regimens, patients receiving novel inductions had lower peak PB CD341 count (70/uL vs. 47/uL; p 5 0.003), however total CD341 cell yield (7.6 Â 10 6 vs. 6.4 Â 10 6 ; p 5 0.07), CD341 dose collected on day 1 (3.9 Â 10 6 vs 3.1 Â 10 6 p 5 0.20) and total number of apheresis sessions (2.6 vs 2.2 p 5 0.068) were not significantly different. Lenalidomide containing regimens when compared to all other regimens (n 5 94) revealed a lower peak PB CD341 count (34/uL vs 59/uL; p 5 0.03) and higher total number of apheresis sessions (3.3 vs 2.3; p 5 0.001). Total CD341 yield (6.8 Â 10 6 vs 7.1 Â 10 6 p 5 0.78) and CD341 cells collected on day 1 (2.6 Â 10 6 vs 3.7 Â 10 6 ; p 5 0.24) were not significantly different. IMiDs as a class when compared to non-IMiD regimens showed significantly lower peak PB CD341 count (45/uL vs 66/uL; p 5 0.004) and higher number of apheresis sessions (2.7 vs 2.2; p 5 0.004). Total CD341 yield (7.6 Â 10 6 vs 6.7 Â 10 6 p 5 0.21) and dose collected on day 1 (3.5 Â 10 6 vs 3.6 Â 10 6 ; p 5 0.91) were not significantly different. A total of 6 patients failed mobilization, including 3 who received lenalidomide.
In conclusion our limited retrospective study shows that CY/G-CSF Mob partially overcomes suppressive effects of lenalidomide on PBSC mobilization by requiring increased number of apheresis sessions. Our data also suggest that impairment of PBSC Mob might be a class-effect of IMiDs, and not merely restricted to lenalidomide, at least in the context of CY/G-CSF Mob.
THE EFFECT OF BODY MASS INDEX ON PATIENT MORTALITY AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Jones, J.L., Hundley, B.C., Salzman, D.E., Koralkar, R., Vaughan, W.P. University of Alabama at Birmingham, Birmingham, AL Background: Elevated body mass index (BMI) is associated with lifelong risk of medical morbidity and has been implicated as a risk factor for mortality after hematopoietic stem cell transplantation HSCT. Previous publications suggest various thresholds for increased mortality. The Center for International Bone Marrow Transplant Research (CIBMTR) threshold for considering obesity a significant comorbidity is a BMI greater than 35. A recent publication using CIBMR data suggested a BMI of 30 was a significant threshold for morbidity and mortality. Objective: To further investigate the association of BMI with excess mortality in a single center analysis, we undertook a survey of 232 consecutive autologous HSCT (aHSCT) patients with myeloma and non-Hodgkin's lymphoma. Patients and Methods: These 232 adult patients studied received their aHSCT at UAB between November 2006 and September 2010. Height and weight were obtained during the final evaluation and consent visit just prior to initiation of preparative therapy, excluding 10 patients with missing one or the other of these variables. Myeloma patients received melphalan 200mg/ M2 (reduced to 140mg/M2 for age greater than 70 or creatinine clearance \ 40mL/min). Non-Hodgkin's lymphoma (NHL) patients received intravenous busulfan targeted to a total exposure of 16000mM*min, cyclophosphamide (5gm/M2) and etoposide (1800 mg/M2). Based upon the reviewed literature, we defined obesity using three BMI cohorts: non-obese\ 35kg/M2, obese 5 35-39kg/M2, morbidly obese
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